Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2160

1.

Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.

Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group, Kremer LCM, Ronckers CM.

Neuro Oncol. 2018 Aug 7. doi: 10.1093/neuonc/noy124. [Epub ahead of print]

PMID:
30099534
2.

Response Assessment of Meningioma: 1D, 2D and Volumetric Criteria for Treatment Response and Tumor Progression.

Huang RY, Unadkat P, Linda Bi W, George E, Preusser M, McCracken DJ, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2018 Aug 2. doi: 10.1093/neuonc/noy126. [Epub ahead of print]

PMID:
30085283
3.

Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.

Cho HJ, Zhao J, Jung SW, Ladewig E, Kong DS, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, Park WY, Park CK, Rabadan R, Nam DH.

Neuro Oncol. 2018 Jul 31. doi: 10.1093/neuonc/noy123. [Epub ahead of print]

PMID:
30085274
4.

Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials.

Hartmann C.

Neuro Oncol. 2018 Aug 1. doi: 10.1093/neuonc/noy112. [Epub ahead of print] No abstract available.

PMID:
30085228
5.

Proton therapy patterns of care among pediatric and adult patients with CNS tumors.

Tseng YD, Hartsell W, Tsai H, Badiyan S, Wang CJ, Rossi C, Kotecha R, Vora S, Vargas C, Larson G, Halasz LM.

Neuro Oncol. 2018 Aug 4. doi: 10.1093/neuonc/noy116. [Epub ahead of print] No abstract available.

PMID:
30085163
6.

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Witt H, Gramatzki D, Hentschel B, Pajtler KW, Felsberg J, Schackert G, Löffler M, Capper D, Sahm F, Sill M, von Deimling A, Kool M, Herrlinger U, Westphal M, Pietsch T, Reifenberger G, Pfister SM, Tonn JC, Weller M; German Glioma Network.

Neuro Oncol. 2018 Jul 24. doi: 10.1093/neuonc/noy118. [Epub ahead of print]

PMID:
30053291
7.

The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have antiproliferative effects.

Kathagen-Buhmann A, Maire CL, Weller J, Schulte A, Matschke J, Holz M, Ligon KL, Glatzel M, Westphal M, Lamszus K.

Neuro Oncol. 2018 Jul 24. doi: 10.1093/neuonc/noy117. [Epub ahead of print]

PMID:
30053149
8.

Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.

Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z.

Neuro Oncol. 2018 Jul 25. doi: 10.1093/neuonc/noy120. [Epub ahead of print]

PMID:
30053126
9.

2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data.

Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ.

Neuro Oncol. 2018 Jul 18. doi: 10.1093/neuonc/noy113. [Epub ahead of print]

PMID:
30020513
10.

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.

Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, Pichler J, Weis S, Kumar R, Webersinke G, Gruber A, Berger W.

Neuro Oncol. 2018 Jul 11. doi: 10.1093/neuonc/noy104. [Epub ahead of print]

PMID:
30010853
11.

Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid / rhabdoid tumor (ATRT).

Nowak J, Nemes K, Hohm A, Vandergrift LA, Hasselblatt M, Johann PD, Kool M, Frühwald MC, Warmuth-Metz M.

Neuro Oncol. 2018 Jul 13. doi: 10.1093/neuonc/noy111. [Epub ahead of print]

PMID:
30010851
12.

Corrigendum.

[No authors listed]

Neuro Oncol. 2018 Jul 10. doi: 10.1093/neuonc/noy106. [Epub ahead of print] No abstract available.

PMID:
29992250
13.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2018 Jul 5. doi: 10.1093/neuonc/noy091. [Epub ahead of print]

PMID:
29982805
14.

Copy number profiling across glioblastoma populations has implications for clinical trial design.

Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, Weller M, Holland EC.

Neuro Oncol. 2018 Jul 2. doi: 10.1093/neuonc/noy108. [Epub ahead of print]

PMID:
29982740
15.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium.

Neuro Oncol. 2018 Mar 21. doi: 10.1093/neuonc/noy046. [Epub ahead of print]

PMID:
29982664
16.

De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.

Theeler BJ.

Neuro Oncol. 2018 Jul 5;20(8):1009-1010. doi: 10.1093/neuonc/noy101. No abstract available.

PMID:
29982653
17.

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Lee EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY.

Neuro Oncol. 2018 Jul 5;20(8):1144. doi: 10.1093/neuonc/noy092. No abstract available.

PMID:
29955870
18.

VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance.

Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P.

Neuro Oncol. 2018 Jun 25. doi: 10.1093/neuonc/noy103. [Epub ahead of print]

PMID:
29939339
19.

Identification of Genomic and Molecular Traits that Present Therapeutic Vulnerability to HGF-targeted therapy in Glioblastoma.

Sa JK, Kim SH, Lee JK, Cho HJ, Shin YJ, Shin H, Koo H, Kim D, Lee M, Kang W, Hong SH, Kim JY, Park YW, Song SW, Lee SJ, Joo KM, Nam DH.

Neuro Oncol. 2018 Jun 23. doi: 10.1093/neuonc/noy105. [Epub ahead of print]

PMID:
29939324
20.

Precision oncology in the era of radiogenomics: the case of D-2HG as an imaging biomarker for mutant IDH gliomas.

Andronesi OC.

Neuro Oncol. 2018 Jun 18;20(7):865-867. doi: 10.1093/neuonc/noy085. No abstract available.

PMID:
29924369

Supplemental Content

Loading ...
Support Center